Compare Citius Pharmaceuticals Inc (CTXR) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Main Street Capital Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Main Street Capital Corporation trades at $53.31 (market cap $4.94B). The key difference: Main Street Capital Corporation is far larger — about 337.4× Citius Pharmaceuticals Inc's market cap, and Main Street Capital Corporation pays a 8.25% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MAIN | |
|---|---|---|
Market Cap | $14.64M | $4.94B |
Sector | Health | Financials |
52-Week High | $1.82 | $67.54 |
52-Week Low | $0.53 | $49.63 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 8.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Main Street Capital (MAIN) trades at $52.51, down 0.62% on the day, with a bullish technical signal from moving averages. The company reported a net income margin of 81.08% for 2025, though revenue dipped to $592M from $601M in 2024. Recent news highlights MAIN's premium valuation among internally managed BDCs and a consistent dividend history, with the latest quarterly earnings showing a mix of beats and misses against expectations.
The outlook is supported by a consensus price target of $57.75, implying upside, but risks include softening earnings and negative operating cash flow. The stock offers a high yield, but investors should weigh the sustainability of dividends against rising expenses and a higher share count noted in recent analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
